<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03986008</url>
  </required_header>
  <id_info>
    <org_study_id>2019050125</org_study_id>
    <nct_id>NCT03986008</nct_id>
  </id_info>
  <brief_title>Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients</brief_title>
  <official_title>Effects of Benaglutide on Weight and Gut Microbiota in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this studay is to evaluate the effects of Benaglutide on the treatment of
      subjects with obesity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">May 23, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 23, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight Change at 3 months</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Measured in kilograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gut microbiota composition</measure>
    <time_frame>3 months</time_frame>
    <description>Gut microbiota composition is assessed by 16S rRNA pyrosequencing. This analysis allows to obtain the relative abundance (%) of the different bacterial taxa and OTUs (operational taxonomic units).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in waist circumference</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Measured in cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic blood pressure</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic blood pressure</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Measured in %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma glucose</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Measured in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in insulin</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Measured in μU/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids-total cholesterol</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Measured in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids-low density lipoprotein cholesterol</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Measured in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids-high density lipoprotein cholesterol</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Measured in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids-triglycerides</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Measured in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids-free fatty acids</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Measured in μmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Uric Acid</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Measured in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in interleukin-10</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Measured in mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tumor necrosis factor</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Measured in mmol/l</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Benaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Benaglutide will be administered three times a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given 10 minutes before each meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liraglutide will be administered once a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given independently of meals and preferably at the same each day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benaglutide</intervention_name>
    <description>The treatment of Benaglutide lasted three months.During the first week: 0.1mg per day;During the second week: 0.14mg per day; From third week onwards, 0.2mg per day.</description>
    <arm_group_label>Benaglutide</arm_group_label>
    <other_name>rhGLP-1(7-36)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>The treatment of Liraglutide lasted three months.During the first week: 0.6mg per day;During the second week: 1.2mg per day; From third week onwards, 1.8mg per day.</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 18 to 65 years (to the date of screening)；

          2. The newly diagnosed obese patients (BMI greater than 28 kg/m2) or abdominal obesity
             (male waist circumference is greater than 90cm, female waist is greater than 85cm).

          3. Nearly a month have not used weight-related drugs,including various weight-loss
             drugs,GLP-1 analogs or agonists,metformin, acarbose,insulin,anti hyperthyroid
             drugs,etc;Or recently used weight-related drugs but the stable dose was more than 1
             month,and the drug dose remained constant or decreased during the trial.

          4. Weight stable for more than 3 months (weight fluctuations &lt;5%).

        Exclusion Criteria:

          1. pregnant female.

          2. Secondary diseases caused by other diseases: including hypothyroidism, increased
             cortisol, hypothalamic and pituitary lesions caused by obesity, all kinds of
             drug-induced obesity, and others.

          3. Severe cardiovascular and cerebrovascular diseases (heart failure, myocardial
             infarction, acute hemorrhagic or ischemic encephalopathy), pulmonary heart disease or
             pulmonary insufficiency, renal failure, severe hepatitis.

          4. Combined with acute complications of diabetes such as ketoacidosis, lactic acidosis,
             hyperosmolar state of diabetes.

          5. Nearly a month had surgery, trauma, infection and so on.

          6. Limb deformity incomplete, difficult to accurately determine the height, weight and
             other physical indicators.

          7. Poor medication compliance or serious side effects (severe rash, syncope, etc.).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Wu</last_name>
    <phone>+8613574120508</phone>
    <email>wujing0731@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Wu</last_name>
      <phone>+86-13574120508</phone>
      <email>wujing0731@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 11, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2019</study_first_posted>
  <last_update_submitted>February 23, 2020</last_update_submitted>
  <last_update_submitted_qc>February 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

